Table 1.

Patient Demographic and Clinical Characteristics of Treated Population

Characteristic	Arm A:IMC-A12 (n = 23)		Arm B: IMC-A12 +C (n = 21)		Arm C: IMC-A12 + C and KRAS Wild Type (n = 20)		All Treatments (N = 64)
	No.	%	No.	%	No.	%	No.	%
Sex
Female	14	61	9	43	10	50	33	52
Male	9	39	12	57	10	50	31	48
Age, years
Median	59		63		62		61
Range	41-79		40-84		44-70		40-84
ECOG performance status
0	3	13	5	24	10	50	18	28
1	20	87	16	76	10	50	46	72
Prior cetuximab	21	91	21	100	20	100	61	95
Prior panitumumab*	7	30	2	10	2	10	11	17
Prior FU, oxaliplatin, irinotecan	23	100	21	100	20	100	64	100

Abbreviations: ECOG, Eastern Cooperative Oncology Group; FU, fluorouracil.

^*Only two patients on trial received panitumumab alone; all other patients also received cetuximab.